Articles By Rob Wright

  1. Does Your Pharma CMO Deliver On Its Promises After Being Acquired? 10/1/2013

    I first met Mark Bamforth, the president and CEO of Gallus BioPharmaceuticals, at a conference shortly after he had acquired/founded his CMO in St. Louis. The company was so new many of the employees at the event didn’t even have business cards.

  2. Private Or Public? Not Really Even A Question In Life Sciences? 8/29/2013

    When launching a start-up in the life sciences industry the question of going public or private could be a struggle. A key driver for the decision to go public is the availability of funding sources and management’s experiences and relationships, says Punit Dhillon, president and CEO of OncoSec Medical Inc.

  3. Can India Achieve cGMP For Vaccines? Does It Matter? 7/31/2013

    Bharat Biotech pledged to sell Rotovac for the rotavirus for $1 a dose to compete with GSK and Merck, if they make it cheaper can they make it safer?

  4. Takeda's Approach To Becoming A Global Player In The Vaccine Market 7/31/2013

    In 2008 Takeda Pharmaceuticals took aim at becoming a global pharmaceutical company by making a number of strategic moves, such as the dissolution of the 23-year, 50/50 joint venture with Abbott, known as TAP Pharmaceuticals, and acquiring Millennium Pharmaceuticals (2008) and Nycomed. These changes strengthened Takeda’s position in two of the largest pharmaceutical markets outside of Japan (U.S. and EU), placing it on the verge of being the first Japanese company to be listed among the 10 largest pharmaceutical companies in the world. With 2012 net sales of $18.4 billion, Takeda ranks twelfth, up four spots from the previous year. What will get them to the next level?

  5. MedImmune's Blueprint For Building A Biologics R&D Engine 5/30/2013

    Bahija Jallal, VP of translational science for MedImmune, has some insights on how to successfully focus your biologics R&D operation to encourage, not kill the entrepreneurial spirit on which it was built.

  6. Can Pharma And Biotech Companies Trust Emerging Markets To Protect IP? 5/30/2013

    How long can or should biotech and pharmaceutical companies continue to conduct business in regions where there is government-enabled IP theft?

  7. Navigating Alnylam To The Brink Of A Breakthrough in RNAi 5/1/2013

    Alnylam went from a small start-up navigating through patent cliff chaos and economic turmoil to position the company toward being on the brink of a big breakthrough in RNAi science.

  8. Africa – The Next Frontier For Novartis Clinical Development 8/1/2012

    Novartis accelerated year-over-year in the emerging market of Sub-Saharan Africa by developing the Region Group Emerging Market (GEM).

  9. GSK's Seekers Of Disruptive Innovation 6/1/2012

    John Baldoni, SVP PTS within GSK, created The Seekers, an idea generation team to stimulate disruptive innovation and serve as a catalyst for creating tipping points sooner. By Rob Wright

  10. Connecting The FDA And Pharma / Biotech Industry 5/16/2012

    Even with more than 8,800 employees and an annual budget of around $3.2 billion, the FDA’s task of protecting the public health seems daunting, considering the complexity of products being developed by industry. By Rob Wright